US20010039049A1 - Erythropoietin-mediated neurogenesis - Google Patents

Erythropoietin-mediated neurogenesis Download PDF

Info

Publication number
US20010039049A1
US20010039049A1 US09/742,484 US74248400A US2001039049A1 US 20010039049 A1 US20010039049 A1 US 20010039049A1 US 74248400 A US74248400 A US 74248400A US 2001039049 A1 US2001039049 A1 US 2001039049A1
Authority
US
United States
Prior art keywords
cells
neurons
erythropoietin
neural stem
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/742,484
Other versions
US6368854B2 (en
Inventor
Samuel Weiss
S. Sorokan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
StemCells California Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22046528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20010039049(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US09/742,484 priority Critical patent/US6368854B2/en
Application filed by Individual filed Critical Individual
Assigned to NEUROSPHERES HOLDINGS LTD. reassignment NEUROSPHERES HOLDINGS LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SOROKAN, S. TODD, WEISS, SAMUEL
Publication of US20010039049A1 publication Critical patent/US20010039049A1/en
Priority to US10/080,161 priority patent/US20020094571A1/en
Priority to US10/095,727 priority patent/US20020098585A1/en
Publication of US6368854B2 publication Critical patent/US6368854B2/en
Application granted granted Critical
Priority to US10/335,477 priority patent/US20030104619A1/en
Priority to US10/930,115 priority patent/US6924142B2/en
Priority to US11/165,546 priority patent/US20060127372A1/en
Assigned to STEMCELLS CALIFORNIA, INC. reassignment STEMCELLS CALIFORNIA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NEUROSPHERES HOLDINGS LTD.
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]

Definitions

  • This invention relates to methods of influencing multipotent neural stem cells to produce progeny that differentiate into neurons by exposing the stem cells and their progeny to erythropoietin.
  • stem cells The role of stem cells in the adult is to replace cells that are lost by natural cell death, injury or disease.
  • the low turnover of cells in the mammalian CNS together with the inability of the adult mammalian CNS to generate new neuronal cells in response to the loss of cells following injury or disease had led to the assumption that the adult mammalian CNS does not contain multipotent neural stem cells.
  • the critical identifying feature of a stem cell is its ability to exhibit self-renewal or to generate more of itself.
  • the simplest definition of a stem cell would be a cell with the capacity for self-maintenance.
  • a more stringent (but still simplistic) definition of a stem cell is provided by Potten and Loeffler (Development, 110:1001, 1990) who have defined stem cells as “undifferentiated cells capable of a) proliferation, b) self-maintenance, c) the production of a large number of differentiated functional progeny, d) regenerating the tissue after injury, and e) a flexibility in the use of these options.”
  • CNS disorders encompass numerous afflictions such as neurodegenerative diseases (e.g. Alzheimer's and Parkinson's), acute brain injury (e.g. stroke, head injury, cerebral palsy) and a large number of CNS dysfunctions (e.g. depression, epilepsy, and schizophrenia).
  • Degeneration in a brain region known as the basal ganglia can lead to diseases with various cognitive and motor symptoms, depending on the exact location.
  • the basal ganglia consists of many separate regions, including the striatum (which consists of the caudate and putamen), the globus pallidus, the substantia nigra, substantia innominate, ventral pallidum, nucleus basalis of Meynert, ventral tegmental area and the subthalamic nucleus.
  • Many motor deficits are a result of neuronal degeneration in the basal ganglia.
  • Huntington's Chorea is associated with the degeneration of neurons in the striatum, which leads to involuntary jerking movements in the host.
  • Degeneration of a small region called the subthalamic nucleus is associated with violent flinging movements of the extremities in a condition called ballismus, while degeneration in the putamen and globus pallidus is associated with a condition of slow writhing movements or athetosis.
  • Other forms of neurological impairment can occur as a result of neural degeneration, such as cerebral palsy, or as a result of CNS trauma, such as stroke and epilepsy.
  • neurodegenerative disease has become an important concern due to the expanding elderly population which is at greatest risk for these disorders.
  • diseases which include Alzheimer's Disease and Parkinson's Disease, have been linked to the degeneration of neuronal cells in particular locations of the CNS, leading to the inability of these cells or the brain region to carry out their intended function.
  • Alzheimer's Disease there is a profound cellular degeneration of the forebrain and cerebral cortex.
  • the nucleus basalis of Meynert appears to be selectively degenerated. This nucleus normally sends cholinergic projections to the cerebral cortex which are thought to participate in cognitive functions including memory.
  • Parkinson's Disease degeneration is seen in another area of the basal ganglia, the substantia nigra par compacta. This area normally sends dopaminergic connections to the dorsal striatum which are important in regulating movement. Therapy for Parkinson's Disease has centered upon restoring dopaminergic activity to this circuit through the use of drugs.
  • Implants of embryonic mesencephalic tissue containing dopamine cells into the caudate and putamen of human patients was shown by Freed et al. ( N Engl J Med 327:1549-1555 (1992)) to offer long-term clinical benefit to some patients with advanced Parkinson's Disease. Similar success was shown by Spencer et al. ( N Engl J Med 327:1541-1548 (1992)). Widner et al. ( N Engl J Med 327:1556-1563 (1992)) have shown long-term functional improvements in patients with MPTP-induced Parkinsonism that received bilateral implantation of fetal mesencephalic tissue. Perlow, et al.
  • the tissue may already be infected with a bacteria or virus, thus requiring expensive diagnostic testing for each fetus used.
  • diagnostic testing might not uncover all infected tissue.
  • the diagnosis of HIV-free tissue is not guaranteed because antibodies to the virus are generally not present until several weeks after infection.
  • a method of producing neurons or neuronal progenitor cells which can be used for transplantation or other purposes comprises inducing multipotent neural stem cells to produce neuronal progenitor cells by proliferating the multipotent neural stem cells in the presence of growth factors and erythropoietin.
  • the erythropoietin may originate from the population of neural cells by subjecting the cells to hypoxic insult which induces neural cells to express erythropoietin.
  • the erythropoietin may be provided exogenously.
  • multipotent or oligopotent neural stem cell refers to an undifferentiated cell which is capable of self-maintenance.
  • a stem cell is capable of dividing without limit.
  • the non-stem cell progeny of a multipotent neural stem cell are termed “progenitor cells.”
  • progenitor cells A distinguishing feature of a progenitor cell is that, unlike a stem cell, it has limited proliferative ability and thus does not exhibit self-maintenance. It is committed to a particular path of differentiation and will, under appropriate conditions, eventually differentiate.
  • a neuronal progenitor cell is capable of a limited number of cell divisions before giving rise to differentiated neurons.
  • a glial progenitor cell likewise is capable of a limited number of cell divisions before giving rise to astrocytes or oligodendrocytes.
  • a neural stem cell is multipotent because its progeny include both neuronal and glial progenitor cells and thus is capable of giving rise to neurons, astrocytes, and oligodendrocytes.
  • EPO erythropoietin
  • Multipotent neural stem cells can be obtained from embryonic, juvenile, or adult mammalian neural tissue (e.g. mouse and other rodents, and humans and other primates) and can be induced to proliferate in vitro or in vivo using the methods disclosed in published PCT application WO 93/01275 and U.S. Pat. No. 5,750,376. Briefly, the administration of one or more growth factors can be used to induce the proliferation of multipotent neural stem cells.
  • Preferred proliferation-inducing growth factors include epidermal growth factor (EGF), amphiregulin, acidic fibroblast growth factor (aFGF or FGF-1), basic fibroblast growth factor (bFGF or FGF-2), transforming growth factor alpha (TGF ⁇ ), and combinations thereof.
  • neural tissue is dissociated and the primary cell cultures are cultured in a suitable culture medium, such as the serum-free defined medium described in Example 1 .
  • a suitable proliferation-inducing growth factor such as EGF (20 ng/ml) is added to the culture medium to induce multipotent neural stem cell proliferation.
  • neurospheres Clusters of undifferentiated neural cells termed “neurospheres”, which after several days in culture, lift off the floor of the culture dish and float in suspension.
  • Each neurosphere results from the proliferation of a single multipotent neural stem cell and is comprised of daughter multipotent neural stem cells and neural progenitor cells.
  • the neurospheres can be dissociated to form a suspension of undifferentiated neural cells and transferred to fresh growth-factor containing medium. This reinitiates proliferation of the stem cells and the formation of new neurospheres. In this manner, an unlimited number of undifferentiated neural stem cell progeny can be produced by the continuous culturing and passaging of the cells in suitable culture conditions.
  • Various procedures are disclosed in WO 94/10292 and U.S. Pat. No. 5,750,376 which can be used to induce the proliferated neural stem cell progeny to differentiate into neurons, astrocytes and oligodendrocytes.
  • the proliferating stem cells can be exposed to EPO.
  • the EPO can be exogenously added at concentrations from about 0.1 to 10 units/ml.
  • the neural cells can be induced to express endogenous EPO by subjecting the cells to hypoxic insult.
  • Subsequent differentiation of the progenitor cell progeny results in at least a two-fold increase in the numbers of neurons generated compared to progeny of stem cells that have not been exposed to EPO, as evidenced by immunocytochemical analysis.
  • Differentiation of cells that have not been exposed to endogenously added EPO or hypoxic insult typically results in a population of cells containing about 3% neurons.
  • the percentage of neurons increases to about 6% with hypoxia treatment, and to about 10% with exposure to exogenous EPO, with the percentage of astrocytes and oligodendrocytes remaining about the same as the control opulations.
  • Cell cultures with an enriched neuronal-progenitor cell and/or neuron population can be used for transplantation to treat various neurological injuries, diseases or disorders.
  • the neuronal progenitor cells or neurons or a combination thereof can be harvested and transplanted into a patient needing neuronal augmentation.
  • Neuronal progenitor cells are particularly suitable for transplantation because they are still undifferentiated and, unlike differentiated neurons, there are no branched processes which can be damaged during transplantation procedures. Once transplanted, the neuronal progenitor cells differentiate in situ into new, functioning neurons. Suitable transplantation methods are known in the art and are disclosed in U.S. Pat. No. 5,750,376.
  • a patient's endogenous multipotent neural stem cells could be induced to proliferate in situ to produce neuronal progenitor cells by administering to the patient a composition comprising one or more growth factors which induces the patient's neural stem cells to proliferate and EPO which instructs the proliferating neural stem cells to produce neuronal progenitor cells which eventually differentiate into neurons.
  • a composition comprising one or more growth factors which induces the patient's neural stem cells to proliferate and EPO which instructs the proliferating neural stem cells to produce neuronal progenitor cells which eventually differentiate into neurons.
  • Suitable methods for administering a composition to a patient which induces the in situ proliferation of the patient's stem cells are disclosed in U.S. Pat. No. 5,750,376.
  • Dissociated cells were centrifuged, the supernatant aspirated, and the cells resuspended at a concentration of about 1 ⁇ 10 5 cell/ml in a serum-free medium, referred to herein as “complete medium” composed of DMEM/F-12 (1:1) including glucose (0.6%), glutamine (2 ⁇ M), sodium bicarbonate (3 mM), and HEPES (4-[2hydroxyethyl]-1-piperazineethanesulfonic acid) buffer (5 mM) (all from Sigma except glutamine [Gibco]).
  • complete medium composed of DMEM/F-12 (1:1) including glucose (0.6%), glutamine (2 ⁇ M), sodium bicarbonate (3 mM), and HEPES (4-[2hydroxyethyl]-1-piperazineethanesulfonic acid) buffer (5 mM) (all from Sigma except glutamine [Gibco]).
  • a defined hormone mix and salt mixture (Sigma) that included insulin (25 ⁇ g/ml), transferrin (100 ⁇ g/ml), progesterone (20 nM), putrescine (60 ⁇ M), and selenium chloride (30 nM) was used in place of serum.
  • the complete medium was supplemented with 20 ng/ml of EGF (Collaborative Research).
  • EGF Collaborative Research
  • Cells were seeded in a T25 culture flask and housed in an incubator at 37° C., 100% humidity, 95% air/5% CO 2 . Stem cells within the cultures began to proliferate within 3-4 days and due to a lack of substrate lifted off the floor of the flask and continued to proliferate in suspension forming neurospheres.
  • Example 1 After 6 days in vitro primary neurospheres formed using the methods described in Example 1 were dissociated and were replated in EGF-containing medium. After 24 hours, the cells were exposed to a modest hypoxic insult by decreasing the concentration of oxygen in the culture medium for varying lengths of time (from 1 to 12 hours) from normal levels of 135 mmHg to 30-40 mmHg. The cells were then cultured in the EGF-containing complete medium described in Example 1 in 95% air/5% CO 2 for 7 days. Hypoxia did not prevent multipotent neural stem cell proliferation, as evidenced by the formation of secondary neurospheres. The number of progeny produced from hypoxia-treated stem cells was the same as that in control cultures not subjected to hypoxic insult.
  • Secondary neurospheres generated from untreated or hypoxia-treated stem cells were dissociated into single cells and induced to differentiate by plating between 0.5 ⁇ 10 6 and 1.0 ⁇ 10 6 cells onto poly-L-ornithine-coated (15 ⁇ g/ml) glass coverslips in 24 well Nuclon (1.0 ml/well) culture dishes in EGF-free complete medium optionally supplemented with 1% FBS. After 7 days, the cells were assayed using immunocytochemical analysis for the presence of neurons. Cultures that had been subjected to hypoxic conditions for 1 to 4 hours had approximately a two-fold increase in the percentage of neurons (approx. 6%) over control cultures (approx.
  • hypoxia-induced factor HIP is a transcription factor for EPO.
  • the 4-hour hypoxia-induced increase in neurogenesis could be blocked by the addition of an EPO-neutralizing antibody at 3 ⁇ g/ml.

Abstract

Methods are described for the production of neurons or neuronal progenitor cells. Multipotent neural stem cells are proliferated in the presence of growth factors and erythropoietin which induces the generation of neuronal progenitor cells. The erythropoietin may be exogenously applied to the multipotent neural stem cells, or alternatively, the cells can be subjected to hypoxic insult which induces the cells to express erythropoietin.

Description

    FIELD OF THE INVENTION
  • This invention relates to methods of influencing multipotent neural stem cells to produce progeny that differentiate into neurons by exposing the stem cells and their progeny to erythropoietin. [0001]
    • BACKGROUND OF THE INVENTION
  • Neurogenesis in mammals is complete early in the postnatal period. Cells of the adult mammalian CNS have little or no ability to undergo mitosis and generate new neurons. While a few mammalian species (e.g. rats) exhibit the limited ability to generate new neurons in restricted adult brain regions such as the dentate gyrus and olfactory bulb (Kaplan, J. Comp. Neurol., 195:323, 1981; Bayer, N.Y. Acad. Sci., 457:163, 1985), the generation of new CNS neurons in adult primates does not normally occur (Rakic, Science, 227:1054, 1985). This inability to produce new nerve cells in most mammals (and especially primates) may be advantageous for long-term memory retention; however, it is a distinct disadvantage when the need to replace lost neuronal cells arises due to injury or disease. [0002]
  • The role of stem cells in the adult is to replace cells that are lost by natural cell death, injury or disease. Until recently, the low turnover of cells in the mammalian CNS together with the inability of the adult mammalian CNS to generate new neuronal cells in response to the loss of cells following injury or disease had led to the assumption that the adult mammalian CNS does not contain multipotent neural stem cells. The critical identifying feature of a stem cell is its ability to exhibit self-renewal or to generate more of itself. The simplest definition of a stem cell would be a cell with the capacity for self-maintenance. A more stringent (but still simplistic) definition of a stem cell is provided by Potten and Loeffler (Development, 110:1001, 1990) who have defined stem cells as “undifferentiated cells capable of a) proliferation, b) self-maintenance, c) the production of a large number of differentiated functional progeny, d) regenerating the tissue after injury, and e) a flexibility in the use of these options.”[0003]
  • CNS disorders encompass numerous afflictions such as neurodegenerative diseases (e.g. Alzheimer's and Parkinson's), acute brain injury (e.g. stroke, head injury, cerebral palsy) and a large number of CNS dysfunctions (e.g. depression, epilepsy, and schizophrenia). Degeneration in a brain region known as the basal ganglia can lead to diseases with various cognitive and motor symptoms, depending on the exact location. The basal ganglia consists of many separate regions, including the striatum (which consists of the caudate and putamen), the globus pallidus, the substantia nigra, substantia innominate, ventral pallidum, nucleus basalis of Meynert, ventral tegmental area and the subthalamic nucleus. Many motor deficits are a result of neuronal degeneration in the basal ganglia. Huntington's Chorea is associated with the degeneration of neurons in the striatum, which leads to involuntary jerking movements in the host. Degeneration of a small region called the subthalamic nucleus is associated with violent flinging movements of the extremities in a condition called ballismus, while degeneration in the putamen and globus pallidus is associated with a condition of slow writhing movements or athetosis. Other forms of neurological impairment can occur as a result of neural degeneration, such as cerebral palsy, or as a result of CNS trauma, such as stroke and epilepsy. [0004]
  • In recent years neurodegenerative disease has become an important concern due to the expanding elderly population which is at greatest risk for these disorders. These diseases, which include Alzheimer's Disease and Parkinson's Disease, have been linked to the degeneration of neuronal cells in particular locations of the CNS, leading to the inability of these cells or the brain region to carry out their intended function. In the case of Alzheimer's Disease, there is a profound cellular degeneration of the forebrain and cerebral cortex. In addition, upon closer inspection, a localized degeneration in an area of the basal ganglia, the nucleus basalis of Meynert, appears to be selectively degenerated. This nucleus normally sends cholinergic projections to the cerebral cortex which are thought to participate in cognitive functions including memory. In the case of Parkinson's Disease, degeneration is seen in another area of the basal ganglia, the substantia nigra par compacta. This area normally sends dopaminergic connections to the dorsal striatum which are important in regulating movement. Therapy for Parkinson's Disease has centered upon restoring dopaminergic activity to this circuit through the use of drugs. [0005]
  • In addition to neurodegenerative diseases, acute brain injuries often result in the loss of neurons, the inappropriate functioning of the affected brain region, and subsequent behavior abnormalities. [0006]
  • To date, treatment for CNS disorders has been primarily via the administration of pharmaceutical compounds. Unfortunately, this type of treatment has been fraught with many complications including the limited ability to transport drugs across the blood-brain barrier and the drug-tolerance which is acquired by patients to whom these drugs are administered long-term. For instance, partial restoration of dopaminergic activity in Parkinson's patients has been achieved with levodopa, which is a dopamine precursor able to cross the blood-brain barrier. However, patients become tolerant to the effects of levodopa, and therefore, steadily increasing dosages are needed to maintain its effects. In addition, there are a number of side effects associated with levodopa such as increased and uncontrollable movement. [0007]
  • Recently, the concept of neurological tissue grafting has been applied to the treatment of neurological diseases such as Parkinson's Disease. Neural grafts may avert the need not only for constant drug administration, but also for complicated drug delivery systems which arise due to the blood-brain barrier. However, there are limitations to this technique as well. First, cells used for transplantation which carry cell surface molecules of a differentiated cell from another host can induce an immune reaction in the host. In addition, the cells must be at a stage of development where they are able to form normal neural connections with neighboring cells. For these reasons, initial studies on neurotransplantation centered on the use of fetal cells. Several studies have shown improvements in patients with Parkinson's Disease after receiving implants of fetal CNS tissue. Implants of embryonic mesencephalic tissue containing dopamine cells into the caudate and putamen of human patients was shown by Freed et al. ([0008] N Engl J Med 327:1549-1555 (1992)) to offer long-term clinical benefit to some patients with advanced Parkinson's Disease. Similar success was shown by Spencer et al. (N Engl J Med 327:1541-1548 (1992)). Widner et al. (N Engl J Med 327:1556-1563 (1992)) have shown long-term functional improvements in patients with MPTP-induced Parkinsonism that received bilateral implantation of fetal mesencephalic tissue. Perlow, et al. describe the transplantation of fetal dopaminergic neurons into adult rats with chemically induced nigrostriatal lesions in “Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system,” Science 204:643-647 (1979). These grafts showed good survival, axonal outgrowth and significantly reduced the motor abnormalities in the host animals.
  • While the studies noted above are encouraging, the use of large quantities of aborted fetal tissue for the treatment of disease raises ethical considerations and political obstacles. There are other considerations as well. Fetal CNS tissue is composed of more than one cell type, and thus is not a well-defined source of tissue. In addition, there are serious doubts as to whether an adequate and constant supply of fetal tissue would be available for transplantation. For example, in the treatment of MPTP-induced Parkinsonism (Widner supra) tissue from 6 to 8 fresh fetuses were required for implantation into the brain of a single patient. There is also the added problem of the potential for contamination during fetal tissue preparation. Moreover, the tissue may already be infected with a bacteria or virus, thus requiring expensive diagnostic testing for each fetus used. However, even diagnostic testing might not uncover all infected tissue. For example, the diagnosis of HIV-free tissue is not guaranteed because antibodies to the virus are generally not present until several weeks after infection. [0009]
  • While currently available transplantation approaches represent a significant improvement over other available treatments for neurological disorders, they suffer from significant drawbacks. The inability in the prior art of the transplant to fully integrate into the host tissue, and the lack of availability of neuronal cells in unlimited amounts from a reliable source for grafting are, perhaps, the greatest limitations of neurotransplantation. A well-defined, reproducible source of neural cells has recently been made available. It has been discovered that multipotent neural stem cells, capable of producing progeny that differentiate into neurons and glia, exist in adult mammalian neural tissue. (Reynolds and Weiss, [0010] Science 255:1707 (1992)). Methods have been provided for the proliferation of these stem cells to provide large numbers of neural cells that can differentiate into neurons and glia (See. U.S. Pat. No. 5,750,376, and International Application No. WO 93/01275). Various factors can be added to neural cell cultures to influence the make-up of the differentiated progeny of multipotent neural stem cell progeny, as disclosed in published PCT application WO 94/10292. Additional methods for directing the differentiation of the stem cell progeny would be desirable.
    • SUMMARY OF THE INVENTION
  • A method of producing neurons or neuronal progenitor cells which can be used for transplantation or other purposes is described. The method comprises inducing multipotent neural stem cells to produce neuronal progenitor cells by proliferating the multipotent neural stem cells in the presence of growth factors and erythropoietin. The erythropoietin may originate from the population of neural cells by subjecting the cells to hypoxic insult which induces neural cells to express erythropoietin. Alternatively, the erythropoietin may be provided exogenously. [0011]
    • DETAILED DESCRIPTION OF THE INVENTION
  • As used herein, the term multipotent or oligopotent neural stem cell refers to an undifferentiated cell which is capable of self-maintenance. Thus, in essence, a stem cell is capable of dividing without limit. The non-stem cell progeny of a multipotent neural stem cell are termed “progenitor cells.” A distinguishing feature of a progenitor cell is that, unlike a stem cell, it has limited proliferative ability and thus does not exhibit self-maintenance. It is committed to a particular path of differentiation and will, under appropriate conditions, eventually differentiate. A neuronal progenitor cell is capable of a limited number of cell divisions before giving rise to differentiated neurons. A glial progenitor cell likewise is capable of a limited number of cell divisions before giving rise to astrocytes or oligodendrocytes. A neural stem cell is multipotent because its progeny include both neuronal and glial progenitor cells and thus is capable of giving rise to neurons, astrocytes, and oligodendrocytes. [0012]
  • Various factors can be added to neural cell cultures to influence the make-up of the differentiated progeny of multipotent neural stem cell progeny, as disclosed in WO 94/10292. It has now been found that erythropoietin (EPO), a hormone thought to influence the differentiative pathway of hematopoietic stem cells and/or their progeny, can increase the number of neuronal progeny that are generated from proliferated multipotent neural stem cells. Multipotent neural stem cells proliferated in the presence of EPO produce a greater percentage of neuronal progenitor cells than multipotent neural stem cells proliferated in the absence of EPO. [0013]
  • Multipotent neural stem cells can be obtained from embryonic, juvenile, or adult mammalian neural tissue (e.g. mouse and other rodents, and humans and other primates) and can be induced to proliferate in vitro or in vivo using the methods disclosed in published PCT application WO 93/01275 and U.S. Pat. No. 5,750,376. Briefly, the administration of one or more growth factors can be used to induce the proliferation of multipotent neural stem cells. Preferred proliferation-inducing growth factors include epidermal growth factor (EGF), amphiregulin, acidic fibroblast growth factor (aFGF or FGF-1), basic fibroblast growth factor (bFGF or FGF-2), transforming growth factor alpha (TGFα), and combinations thereof. For the proliferation of multipotent neural stem cells in vitro, neural tissue is dissociated and the primary cell cultures are cultured in a suitable culture medium, such as the serum-free defined medium described in Example [0014] 1. A suitable proliferation-inducing growth factor, such as EGF (20 ng/ml) is added to the culture medium to induce multipotent neural stem cell proliferation.
  • In the absence of substrates that promote cell adhesion (e.g. ionically charged surfaces such as poly-L-lysine and poly-L-ornithine coated and the like), multipotent neural stem cell proliferation can be detected by the formation of clusters of undifferentiated neural cells termed “neurospheres”, which after several days in culture, lift off the floor of the culture dish and float in suspension. Each neurosphere results from the proliferation of a single multipotent neural stem cell and is comprised of daughter multipotent neural stem cells and neural progenitor cells. The neurospheres can be dissociated to form a suspension of undifferentiated neural cells and transferred to fresh growth-factor containing medium. This reinitiates proliferation of the stem cells and the formation of new neurospheres. In this manner, an unlimited number of undifferentiated neural stem cell progeny can be produced by the continuous culturing and passaging of the cells in suitable culture conditions. [0015]
  • Various procedures are disclosed in WO 94/10292 and U.S. Pat. No. 5,750,376 which can be used to induce the proliferated neural stem cell progeny to differentiate into neurons, astrocytes and oligodendrocytes. To increase the number of neuronal progenitor cells that are produced by the multipotent neural stem cells, the proliferating stem cells can be exposed to EPO. The EPO can be exogenously added at concentrations from about 0.1 to 10 units/ml. Alternatively, the neural cells can be induced to express endogenous EPO by subjecting the cells to hypoxic insult. Subsequent differentiation of the progenitor cell progeny results in at least a two-fold increase in the numbers of neurons generated compared to progeny of stem cells that have not been exposed to EPO, as evidenced by immunocytochemical analysis. Differentiation of cells that have not been exposed to endogenously added EPO or hypoxic insult typically results in a population of cells containing about 3% neurons. The percentage of neurons increases to about 6% with hypoxia treatment, and to about 10% with exposure to exogenous EPO, with the percentage of astrocytes and oligodendrocytes remaining about the same as the control opulations. [0016]
  • Washout experiments, in which the growth factor/EPO medium is removed after 24 hours and changed to regular growth factor-containing medium, reveals that the EPO instructs the stem cells prior to their first cell division, to produce more neurons. The continued presence of EPO after the initial 24 hours does not result in a further increase in the numbers of neurons over cultures subjected to EPO for a 24 hour period. [0017]
  • The ability to manipulate the fate of the differentiative pathway of the multipotent neural stem cell progeny to produce more neuronal progenitor cells and neurons is beneficial. Cell cultures that contain a higher percentage of neuronal progenitor cells and/or neurons will be useful for screening the effects of various drugs and other agents on neuronal cells. Methods for screening the effect of drugs on cell cultures are well known in the art and are also disclosed in U.S. Pat. No. 5,750,376. [0018]
  • Cell cultures with an enriched neuronal-progenitor cell and/or neuron population can be used for transplantation to treat various neurological injuries, diseases or disorders. The neuronal progenitor cells or neurons or a combination thereof can be harvested and transplanted into a patient needing neuronal augmentation. Neuronal progenitor cells are particularly suitable for transplantation because they are still undifferentiated and, unlike differentiated neurons, there are no branched processes which can be damaged during transplantation procedures. Once transplanted, the neuronal progenitor cells differentiate in situ into new, functioning neurons. Suitable transplantation methods are known in the art and are disclosed in U.S. Pat. No. 5,750,376. [0019]
  • Alternatively, a patient's endogenous multipotent neural stem cells could be induced to proliferate in situ to produce neuronal progenitor cells by administering to the patient a composition comprising one or more growth factors which induces the patient's neural stem cells to proliferate and EPO which instructs the proliferating neural stem cells to produce neuronal progenitor cells which eventually differentiate into neurons. Suitable methods for administering a composition to a patient which induces the in situ proliferation of the patient's stem cells are disclosed in U.S. Pat. No. 5,750,376. [0020]
  • All cited references, patents and applications are herein incorporated in their entireties by reference.[0021]
    • EXAMPLE 1 Multipotent neural stem cell proliferation
  • Striata from 14-day-old mouse embryos were removed using sterile procedure. Tissue was mechanically dissociated into serum-free medium composed of a 1:1 mixture of Dulbecco's modified Eagle's medium (DMEM) and F-12 nutrient (Gibco). Dissociated cells were centrifuged, the supernatant aspirated, and the cells resuspended at a concentration of about 1×10[0022] 5 cell/ml in a serum-free medium, referred to herein as “complete medium” composed of DMEM/F-12 (1:1) including glucose (0.6%), glutamine (2 μM), sodium bicarbonate (3 mM), and HEPES (4-[2hydroxyethyl]-1-piperazineethanesulfonic acid) buffer (5 mM) (all from Sigma except glutamine [Gibco]). A defined hormone mix and salt mixture (Sigma) that included insulin (25 μg/ml), transferrin (100 μg/ml), progesterone (20 nM), putrescine (60 μM), and selenium chloride (30 nM) was used in place of serum. The complete medium was supplemented with 20 ng/ml of EGF (Collaborative Research). Cells were seeded in a T25 culture flask and housed in an incubator at 37° C., 100% humidity, 95% air/5% CO2. Stem cells within the cultures began to proliferate within 3-4 days and due to a lack of substrate lifted off the floor of the flask and continued to proliferate in suspension forming neurospheres.
    • EXAMPLE 2 Hypoxia-induced neurogenesis
  • After 6 days in vitro primary neurospheres formed using the methods described in Example 1 were dissociated and were replated in EGF-containing medium. After 24 hours, the cells were exposed to a modest hypoxic insult by decreasing the concentration of oxygen in the culture medium for varying lengths of time (from 1 to 12 hours) from normal levels of 135 mmHg to 30-40 mmHg. The cells were then cultured in the EGF-containing complete medium described in Example 1 in 95% air/5% CO[0023] 2 for 7 days. Hypoxia did not prevent multipotent neural stem cell proliferation, as evidenced by the formation of secondary neurospheres. The number of progeny produced from hypoxia-treated stem cells was the same as that in control cultures not subjected to hypoxic insult.
  • Secondary neurospheres generated from untreated or hypoxia-treated stem cells were dissociated into single cells and induced to differentiate by plating between 0.5×10[0024] 6 and 1.0×106 cells onto poly-L-ornithine-coated (15 μg/ml) glass coverslips in 24 well Nuclon (1.0 ml/well) culture dishes in EGF-free complete medium optionally supplemented with 1% FBS. After 7 days, the cells were assayed using immunocytochemical analysis for the presence of neurons. Cultures that had been subjected to hypoxic conditions for 1 to 4 hours had approximately a two-fold increase in the percentage of neurons (approx. 6%) over control cultures (approx. 3%) Cultures subjected to 4 to 8 hours of hypoxia had fewer neurons produced and cultures subjected to about 12 hours of hypoxia had normal levels (approx. 3%). The hypoxic insult induced a rapid up-regulation of hypoxia-induced factor (HIF) in the multipotent neural stem cell progeny. HIP is a transcription factor for EPO. The 4-hour hypoxia-induced increase in neurogenesis could be blocked by the addition of an EPO-neutralizing antibody at 3 μg/ml.
    • EXAMPLE 3 Erythropoietin-induced Neurogenesis
  • After 6 days in vitro primary neurospheres formed using the methods described in Example 1 were dissociated and replated in complete medium containing EGF at 20 ng/ml and human recombinant EPO at 0.1 to 10 units/ml for either 24 hours or 7 days under normal oxygen conditions (95% air/5% Co[0025] 2; 135 mmHg). In both cases, immunocytochemistry revealed an EPO dose-dependent three-fold increase in the numbers of neurons generated.

Claims (5)

What is claimed is:
1. A method of producing neurons from a population of neural cells containing at least one multipotent neural stem cell comprising inducing said at least one multipotent neural stem cell to proliferate in the presence of erythropoietin to produce neuronal progenitor cells and allowing said neuronal progenitor cells to differentiate into neurons.
2. The method of
claim 1
 wherein said population of neural cells is induced to express said erythropoietin by subjecting said population of neural cells to hypoxic insult.
3. The method of
claim 1
 wherein said erythropoietin is exogenously added.
4. The method of
claim 1
 wherein at least one exogenously added growth factor induces said at least one multipotent neural stem cell to proliferate.
5. The method of
claim 4
 wherein said exogenously added growth factor is epidermal growth factor.
US09/742,484 1997-10-24 2000-12-20 Hypoxia mediated neurogenesis Expired - Fee Related US6368854B2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US09/742,484 US6368854B2 (en) 1997-10-24 2000-12-20 Hypoxia mediated neurogenesis
US10/080,161 US20020094571A1 (en) 1997-10-24 2002-02-21 Hypoxia-mediated neurogenesis
US10/095,727 US20020098585A1 (en) 1997-10-24 2002-03-12 Hypoxia-mediated neurogenesis
US10/335,477 US20030104619A1 (en) 1997-10-24 2002-12-31 Hypoxia-mediated neurogenesis
US10/930,115 US6924142B2 (en) 1997-10-24 2004-08-31 Hypoxia-mediated neurogenesis assay
US11/165,546 US20060127372A1 (en) 1997-10-24 2005-06-23 Hypoxia-mediated neurogenesis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6304097P 1997-10-24 1997-10-24
US09/175,890 US6165783A (en) 1997-10-24 1998-10-20 Erythropoietin-mediated neurogenesis
US09/742,484 US6368854B2 (en) 1997-10-24 2000-12-20 Hypoxia mediated neurogenesis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/175,890 Continuation US6165783A (en) 1997-10-24 1998-10-20 Erythropoietin-mediated neurogenesis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/080,161 Continuation US20020094571A1 (en) 1997-10-24 2002-02-21 Hypoxia-mediated neurogenesis
US10/095,727 Continuation US20020098585A1 (en) 1997-10-24 2002-03-12 Hypoxia-mediated neurogenesis

Publications (2)

Publication Number Publication Date
US20010039049A1 true US20010039049A1 (en) 2001-11-08
US6368854B2 US6368854B2 (en) 2002-04-09

Family

ID=22046528

Family Applications (7)

Application Number Title Priority Date Filing Date
US09/175,890 Expired - Lifetime US6165783A (en) 1997-10-24 1998-10-20 Erythropoietin-mediated neurogenesis
US09/742,484 Expired - Fee Related US6368854B2 (en) 1997-10-24 2000-12-20 Hypoxia mediated neurogenesis
US10/080,161 Abandoned US20020094571A1 (en) 1997-10-24 2002-02-21 Hypoxia-mediated neurogenesis
US10/095,727 Abandoned US20020098585A1 (en) 1997-10-24 2002-03-12 Hypoxia-mediated neurogenesis
US10/335,477 Abandoned US20030104619A1 (en) 1997-10-24 2002-12-31 Hypoxia-mediated neurogenesis
US10/930,115 Expired - Fee Related US6924142B2 (en) 1997-10-24 2004-08-31 Hypoxia-mediated neurogenesis assay
US11/165,546 Abandoned US20060127372A1 (en) 1997-10-24 2005-06-23 Hypoxia-mediated neurogenesis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/175,890 Expired - Lifetime US6165783A (en) 1997-10-24 1998-10-20 Erythropoietin-mediated neurogenesis

Family Applications After (5)

Application Number Title Priority Date Filing Date
US10/080,161 Abandoned US20020094571A1 (en) 1997-10-24 2002-02-21 Hypoxia-mediated neurogenesis
US10/095,727 Abandoned US20020098585A1 (en) 1997-10-24 2002-03-12 Hypoxia-mediated neurogenesis
US10/335,477 Abandoned US20030104619A1 (en) 1997-10-24 2002-12-31 Hypoxia-mediated neurogenesis
US10/930,115 Expired - Fee Related US6924142B2 (en) 1997-10-24 2004-08-31 Hypoxia-mediated neurogenesis assay
US11/165,546 Abandoned US20060127372A1 (en) 1997-10-24 2005-06-23 Hypoxia-mediated neurogenesis

Country Status (5)

Country Link
US (7) US6165783A (en)
JP (1) JP2001520878A (en)
AU (1) AU9617398A (en)
CA (1) CA2307017C (en)
WO (1) WO1999021966A1 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
US6610540B1 (en) * 1998-11-18 2003-08-26 California Institute Of Technology Low oxygen culturing of central nervous system progenitor cells
DE19857609A1 (en) 1998-12-14 2000-06-15 Hannelore Ehrenreich Use of erythropoietin for the treatment of human cerebral ischemia
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
DE19928210B4 (en) * 1999-06-19 2005-08-18 Neuroprogen Gmbh Leipzig Neuronal cell material and method for its production
CA2377906A1 (en) * 1999-07-16 2001-01-25 Neurotrophic Bioscience, Inc. Methods for producing and preparing cells for cell therapy
WO2001058460A1 (en) * 2000-02-11 2001-08-16 The Schepens Eye Research Institute, Inc. Isolation and transplantation of retinal stem cells
IL153079A0 (en) * 2000-05-26 2003-06-24 Ortho Mcneil Pharm Inc Neuroprotective peptides
US7259146B2 (en) * 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
AU2001267882A1 (en) * 2000-06-30 2002-01-14 Chugai Seiyaku Kabushiki Kaisha Preventives and remedies for diseases in association with demyelination
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
JP2005501801A (en) 2001-02-02 2005-01-20 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Neurological dysfunction treatment comprising fructopyranose sulfamate and erythropoietin
US7838292B1 (en) 2001-03-29 2010-11-23 University Of Louisville Research Foundation, Inc. Methods for obtaining adult human olfactory progenitor cells
WO2003018782A2 (en) * 2001-08-30 2003-03-06 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
KR100505152B1 (en) * 2001-09-10 2005-08-03 (주)가이아진 Method for production of erythropoietin using ascorbic acid
AR036401A1 (en) * 2001-09-14 2004-09-08 Stem Cell Therapeutics Inc INCREASE IN THE AMOUNT OF NEURONAL MOTHER CELLS INDUCED BY PROLACTIN.
AU2002325710A1 (en) * 2001-09-18 2003-04-01 Stem Cell Therapeutics Inc. Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
JP2005514926A (en) 2002-01-14 2005-05-26 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ Novel mammalian multipotent stem cells and compositions, methods for their preparation and administration
WO2003078959A2 (en) * 2002-03-11 2003-09-25 Ortho Mcneil Pharmaceutical, Inc Methods for shp1 mediated neuroprotection
US7439063B2 (en) * 2002-06-11 2008-10-21 Burnham Institute For Medical Research Neuroprotective synergy of erythropoietin and insulin-like growth factors
BR0312395A (en) * 2002-07-01 2007-06-19 Kenneth S Warren Inst Inc recombinant mutein protective tissue cytokine, mammalian cell responsive recombinant tissue protective cytokine, isolated nucleic acid molecule, vector, expression vector, genetically engineered cell, cell, pharmaceutical composition, method for protecting, maintaining or enhancing the viability of a cell, tissue or organ isolated from a mammalian body, use of a recombinant tissue protective cytokine, method for facilitating the transcytosis of a molecule through an endothelial cell barrier in a mammal, and composition for transporting a molecule through of transcytosis through an endothelial cell barrier
US7368115B2 (en) * 2002-07-31 2008-05-06 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (PACAP)
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
WO2004075818A2 (en) * 2003-02-26 2004-09-10 Proteosys Ag Stress specific molecular response in neurons
US20040209812A1 (en) * 2003-03-27 2004-10-21 Renzi Michael J. Use of erythropoietin in stroke recovery
US7459152B2 (en) * 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
JP4620052B2 (en) * 2003-09-12 2011-01-26 ステムセル テクノロジーズ インコーポレーティッド Nerve colony formation assay
US7546127B2 (en) * 2003-09-26 2009-06-09 Siemens Communications, Inc. System and method for centrally-hosted presence reporting
CN1897959A (en) * 2003-09-29 2007-01-17 沃伦药品公司 Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
RU2542391C2 (en) * 2003-12-30 2015-02-20 Аугустинус БАДЕР Method for neogenesis
EP1550715A1 (en) * 2003-12-30 2005-07-06 Bionethos Holding Gmbh Method for the regeneration of tissue
WO2005079250A2 (en) * 2004-02-13 2005-09-01 Cornell Research Foundation, Inc. Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom
AU2005211847B2 (en) * 2004-02-13 2011-02-24 Stem Cell Therapeutics Corp. Use of luteinizing hormone (LH) and chorionic gonadotropin (hCG) for proliferation of neural stem cells and neurogenesis
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
EP2317316A3 (en) * 2005-07-08 2011-06-15 Braincells, Inc. Methods for identifying agent and conditions that modulate neurogenesis
WO2007027905A2 (en) * 2005-08-31 2007-03-08 Science And Technology Corporation @ Unm Human renal stem cells
US7534765B2 (en) * 2005-09-27 2009-05-19 Stem Cell Therapeutics Corp. Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin
US20070077200A1 (en) * 2005-09-30 2007-04-05 Baker Clark R Method and system for controlled maintenance of hypoxia for therapeutic or diagnostic purposes
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
AR053416A1 (en) * 2005-11-10 2007-05-09 Protech Pharma S A COMBINATION OF GLICOISOFORMS FOR THE TREATMENT OR PREVENTION OF SEPTICEMIA, TRANSGENIC CELLULAR LINE PRODUCING ERYTHROPOYETINE GLICOFORMES, PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMBINATION, PROCEDURES TO OBTAIN THE CELLULAR PROCEDURE
CN101495078B (en) * 2006-02-08 2013-02-13 Cvac系统有限公司 Combination pressure therapy
US20070193578A1 (en) * 2006-02-08 2007-08-23 Cvac Systems, Inc. Combination Pressure Therapy for Treatment of Ischemia & Heart Conditions, Diabetes, Alzheimer's Disease and Cancer
WO2008106410A1 (en) 2007-02-26 2008-09-04 Cvac Systems, Inc. Combination pressure therapy for treatment of serum lipid levels, steroid levels, and steroidogenesis
US8899228B2 (en) 2006-02-08 2014-12-02 Cvac Systems, Inc. Combination pressure therapy for treatment of chronic pain
JP2009530234A (en) * 2006-03-17 2009-08-27 ステム セル セラピューティクス コーポレイション Administration regimen for LH or HCG and EPO for the treatment of neurodegenerative diseases
AU2007285763B2 (en) * 2006-08-18 2011-12-15 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
US8895303B2 (en) 2006-11-13 2014-11-25 Charite-Universitatsmedizin Berlin Method of cell culture and method of treatment comprising a vEPO protein variant
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
EP2182980A4 (en) * 2007-07-27 2012-04-18 Armagen Technologies Inc Methods and compositions for increasing alpha-iduronidase activity in the cns
CN101939443B (en) 2008-02-08 2014-01-29 Ambrx公司 Modified leptin polypeptides and their uses
UA103774C2 (en) 2008-07-23 2013-11-25 Амбркс, Інк. Modified bovine g-csf polypeptides and their uses
WO2010036964A2 (en) 2008-09-26 2010-04-01 Ambrx Inc. Modified animal erythropoietin polypeptides and their uses
US8790638B2 (en) * 2009-02-04 2014-07-29 Stemedica Cell Technologies, Inc. Compositions of stem cells and stem cell factors and methods for their use and manufacture
EP2408474B1 (en) 2009-03-18 2019-06-26 Armagen, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
SI2485761T1 (en) * 2009-10-09 2019-05-31 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
AR083006A1 (en) 2010-09-23 2013-01-23 Lilly Co Eli FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
WO2013081706A1 (en) 2011-12-02 2013-06-06 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
EP2814947B1 (en) 2012-02-17 2018-11-21 Schepens Eye Research Institute Phenotype profile of human retinal progenitor cells
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
KR102056447B1 (en) * 2018-03-16 2019-12-16 (주)메디노 A Method for inducing angiogenesis using neural stem cell
CN110713982A (en) * 2019-11-25 2020-01-21 深圳科学之门生物工程有限公司 Culture medium for rapid amplification of neural stem cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
ES2198404T5 (en) * 1991-07-08 2008-05-01 Neurospheres Holdings Ltd. NEURAL PROGENITOR CELLS THAT RESPOND TO GROWTH FACTOR AND THAT CAN BE PROLIFERED IN VITRO.
ES2194016T5 (en) * 1992-10-28 2007-11-16 Neurospheres Holdings Ltd. BIOLOGICAL FACTORS AND NEURAL GERMINAL CELLS.
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
CN1141058A (en) * 1993-11-09 1997-01-22 纽罗斯菲里斯控股有限公司 In situ modification and manipulation of stem cells of the central nervous system
AU716811B2 (en) * 1994-11-14 2000-03-09 Neurospheres Holdings Ltd Regulation of neural stem cell proliferation
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis

Also Published As

Publication number Publication date
US6368854B2 (en) 2002-04-09
US20020098585A1 (en) 2002-07-25
US6165783A (en) 2000-12-26
US20030104619A1 (en) 2003-06-05
JP2001520878A (en) 2001-11-06
AU9617398A (en) 1999-05-17
CA2307017C (en) 2014-01-28
CA2307017A1 (en) 1999-05-06
US20060127372A1 (en) 2006-06-15
US6924142B2 (en) 2005-08-02
US20050026136A1 (en) 2005-02-03
US20020094571A1 (en) 2002-07-18
WO1999021966A1 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
US6368854B2 (en) Hypoxia mediated neurogenesis
CA2155024C (en) Genetic modification of neural stem cells
JP4023822B2 (en) In vitro induction of dopaminergic cells
AU716811B2 (en) Regulation of neural stem cell proliferation
EP0594669B9 (en) Growth factor-responsive neural progenitor cells which can be proliferated in vitro.
EP1570052B1 (en) Method for culturing neural stem cells using hepatocyte growth factor
US20070111932A1 (en) Method of enhancing and/or inducing neuronal migration using erythropoietin
CA2492434A1 (en) Method of enhancing and/or inducing neuronal migration using erythropoietin
MXPA97003493A (en) In vitro induction of dopaminergi cells
WO2001090315A2 (en) Production of neurons from stem cells
CA2204630A1 (en) Regulation of neural stem cell proliferation
CA2399589A1 (en) Novel growth factor-responsive progenitor cells which can be proliferated in vitro
MXPA97003492A (en) Regulation of proliferation of cells germinal neural

Legal Events

Date Code Title Description
AS Assignment

Owner name: NEUROSPHERES HOLDINGS LTD., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WEISS, SAMUEL;SOROKAN, S. TODD;REEL/FRAME:012233/0616;SIGNING DATES FROM 19980116 TO 19981015

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: STEMCELLS CALIFORNIA, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NEUROSPHERES HOLDINGS LTD.;REEL/FRAME:031508/0106

Effective date: 20131023

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20140409